Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 6, 2012, Pages 2039-2049

  Fleseriu, Maria ^a   Biller, Beverly M K ^b   Findling, James W ^c   Molitch, Mark E ^d   Schteingart, David E ^e   Gross, Coleman ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f Corcept Therapeutics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DEXAMETHASONE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MIFEPRISTONE; SPIRONOLACTONE;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHING SYNDROME; DECREASED APPETITE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKNENING; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOKALEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA BLEEDING; VOMITING; WAIST CIRCUMFERENCE; WEIGHT CHANGE;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY WEIGHT; CUSHING SYNDROME; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; HYPERTENSION; MALE; MIDDLE AGED; MIFEPRISTONE; QUALITY OF LIFE; QUINOLINES; RECEPTORS, GLUCOCORTICOID; UREA;

EID: 84861967547     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3350     Document Type: Article

References (42)

1. Clayton RN, Raskauskiene D, Reulen RC, Jones PW 2011 Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632-642
2. Etxabe J, Vazquez JA 1994 Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 40: 479-484 (Pubitemid 24194645)
3. Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J 2001 Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86:117-123 (Pubitemid 32111743)
4. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M 2008 Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93: 2454-2462 (Pubitemid 352008503)
5. Findling JW, Raff H 2006 Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91:3746-3753 (Pubitemid 44536836)
6. Loeffler JS, Shih HA 2011 Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992-2003
7. Pivonello R, DeMartino MC, DeLeo M, Lombardi G, Colao A 2008 Cushing's syndrome. Endocrinol Metab Clin North Am 37:135-149
8. Schteingart DE 2009 Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 14:661-671
9. Castinetti F, Conte-Devolx B, Brue T 2010 Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology 92(Suppl 1):125-130
10. Bourgeois S, Pfahl M, Baulieu EE 1984 DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486. EMBO J 3:751-755
11. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lähteenmäki P 1987 Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 26:279-284 (Pubitemid 17040134)
12. Beaufrère B, de Parscau L, Chatelain P, Morel Y, Aguercif M, Francois R 1987 RU 486 administration in a child with Cushing's syndrome. Lancet 2:217 (Pubitemid 17091874)
13. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP 1986 Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 63: 639-643 (Pubitemid 16050563)
14. Chrousos GP, Laue L, Nieman LK, Udelsman R, Kawai S, Loriaux DL 1989 Clinical applications of RU 486, a prototype glucocorticoid and progestin antagonist. In: Mantero F, Takeda R, Scoggins BA, Biglieri EG, Funder J, eds. The adrenal and hypertension: from cloning to clinic. New York: Raven Press; 273-284
15. Nieman LK, Udelsman R, Loriaux DL, Chrousos GP 1987 Antiglucocorticoids. In: D'Agata R, Chrousos GP, eds. Recent advances in adrenal regulation and function. New York: Raven Press; 235-242
16. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL 1985 Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536-540 (Pubitemid 15243969)
17. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D 2001 Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568-3573 (Pubitemid 32755945)
18. van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW 1991 Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone(RU486). Ann Intern Med 114:143-144
19. Newfield RS, Spitz IM, Isacson C, New MI 2001 Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 54:399-404 (Pubitemid 32234206)
20. Oosterhuis JK, van den Berg G, Monteban-Kooistra WE, Ligtenberg JJ, Tulleken JE, Meertens JH, Zijlstra JG 2007 Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome. Neth J Med 65:215-217 (Pubitemid 47007916)
21. Cassier PA, Abou-Amara-Olivieri S, Artru P, Lapalus MG, Riou JP, Lombard-Bohas C 2008 Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases. Eur J Endocrinol 158:935-938 (Pubitemid 351837384)
22. Donckier JE, Michel LA, Berbinschi A, De Coster PM, De Plaen JF, Ketelslegers JM, Buysschaert M 1989 Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane. Surgery 105:690-692 (Pubitemid 19126041)
23. Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW 2007 Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest 30:776-779 (Pubitemid 350238205)
24. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B 2009 Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 160:1003-1010
25. de Bruin C, Hofland LJ, Nieman LK, van Koetsveld PM, Waaijers AM, Sprij-Mooij DM, van Essen M, Lamberts SW, de Herder WW, Feelders RA 2012 Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab 97: 455-462
26. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P 2004 Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076 (Pubitemid 39628416)
27. Doshi A, Zaheer A, Stiller MJ 1997 A comparison of current acne grading systems and proposal of a novel system. Int J Derm 36:416-418
28. Hatch R, Rosenfield RL, Kim MH, Tredway D 1981 Hirsutism: implications, etiology and management. Am J Obstet Gynecol 140: 815-830
29. Beck AT, Steer RA, Brown G 1996 Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corp.
30. Reitan RM, Wolfson D 1985 Halstead-Reitan Neuropsychological test battery: theory and clinical interpretation. Tucson, AZ: Neuropsychological Press
31. Tombaugh TN 2004 Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203-214 (Pubitemid 38316871)
32. Ware JE Jr., Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME 2007 User's manual for the SF-36v2 Health Survey. 2nd ed. Lincoln, RI: Quality Metric Inc.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
34. Taylor HC, McLean S, Monheim K 2003 Resolution of Cushing's disease followed by secondary adrenal insufficiency after anticoagulant- associated pituitary hemorrhage. Endocr Pract 9:147-151
35. Boscaro M, Arnaldi G 2009 Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab 94:3121-3131
36. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM 2008 The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93:1526-1540 (Pubitemid 351656485)
37. Mullan KR, Atkinson AB 2008 Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism. Clin Endocrinol (Oxf) 68:327-337 (Pubitemid 351257845)
38. Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X 2007 Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab 92: 172-179 (Pubitemid 46067527)
39. Porterfield JR, Thompson GB, Young Jr WF, Chow JT, Fryrear RS, van Heerden JA, Farley DR, Atkinson JL, Meyer FB, Abboud CF, Nippoldt TB, Natt N, Erickson D, Vella A, Carpenter PC, Richards M, Carney JA, Larson D, Schleck C, Churchward M, Grant CS 2008 Surgery for Cushing's syndrome: an historical review and recent ten-year experience. World J Surg 32:659-677
40. Sitruk-Ware R, Spitz IM 2003 Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 68:409-420 (Pubitemid 38112739)
41. van Uum SH, Lenders JW, Hermus AR 2004 Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. Semin Vasc Med 4:121-128
42. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams AR, Blithe DL 2008 The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 21:591-598 (Pubitemid 351589653)